Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Predictors of the Metabolic Effect of Sleep Loss

Not Applicable

Completed

Conditions: Apnea
Obstructive Sleep Apnea (OSA)
Obesity

Interventions: Other: Restriction
Other: Extension

First Posted Date: 2009-08-26

Last Posted Date: 2013-09-05

Lead Sponsor: University of Chicago

Target Recruit Count: 30

Registration Number: NCT00965783

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Clinical and Economic Implications of Genetic Testing for Warfarin Management

Phase 4

Completed

Conditions: Blood Coagulation Disorders

Interventions: Drug: Warfarin

First Posted Date: 2009-08-24

Last Posted Date: 2019-11-25

Lead Sponsor: University of Chicago

Target Recruit Count: 359

Registration Number: NCT00964353

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Chicago Social Drinking Project

Not Applicable

Recruiting

Conditions: Alcoholism

Interventions: Drug: Placebo
Drug: Diphenhydramine
Drug: Ethanol
Drug: Caffeine

First Posted Date: 2009-08-19

Last Posted Date: 2024-01-29

Lead Sponsor: University of Chicago

Target Recruit Count: 800

Registration Number: NCT00961792

Locations: 🇺🇸
Clinical Addictions Research Laboratory, Chicago, Illinois, United States

Comparison of Two Methods of Securing Skin Grafts Using Negative Pressure Wound Therapy: Vacuum Assisted Closure (VAC) and Gauze Suction (GSUC)

Phase 3

Completed

Conditions: Wound Healing

Interventions: Device: VAC
Device: GSUC

First Posted Date: 2009-08-04

Last Posted Date: 2015-09-24

Lead Sponsor: University of Chicago

Target Recruit Count: 104

Registration Number: NCT00952120

Locations: 🇺🇸
University of Chicago Medical Center, Section of Plastic and Reconstructive Surgery, Chicago, Illinois, United States

Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Leukemia
Advanced Hematologic Malignancies
Preleukemia

Interventions: Drug: Clofarabine
Drug: Melphalan
Drug: Campath
Procedure: Stem Cell Transplant

First Posted Date: 2009-07-22

Last Posted Date: 2014-02-27

Lead Sponsor: University of Chicago

Target Recruit Count: 82

Registration Number: NCT00943592

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies

Phase 1

Terminated

Conditions: Preleukemia
Myeloproliferative Disorders
Lymphoma
Myeloma
Graft Versus Host Disease

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: Campath

First Posted Date: 2009-07-22

Last Posted Date: 2014-03-17

Lead Sponsor: University of Chicago

Target Recruit Count: 1

Registration Number: NCT00943293

Locations: 🇺🇸
The Uniiversity of Chicago, Chicago, Illinois, United States

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

Phase 1

Completed

Conditions: Lymphoma
Leukemia
Myeloma

Interventions: Drug: Busulfan
Drug: Fludarabine
Drug: Campath
Procedure: Stem Cell Transplant

First Posted Date: 2009-07-22

Last Posted Date: 2019-02-04

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT00943319

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Combined Haploidentical-Cord Blood Transplantation for Adults and Children

Not Applicable

Completed

Conditions: Multiple Myeloma
Leukemia
Lymphoma
Myelodysplastic Syndrome

Interventions: Drug: Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)
Procedure: Stem Cell Transplant
Procedure: Stem Cells Collections
Drug: Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)
Drug: Fludarabine, Busulfan, and ATG

First Posted Date: 2009-07-22

Last Posted Date: 2021-01-27

Lead Sponsor: University of Chicago

Target Recruit Count: 87

Registration Number: NCT00943800

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Tolcapone Treatment of Pathological Gambling

Phase 2

Completed

Conditions: Pathological Gambling

Interventions: Drug: Tolcapone

First Posted Date: 2009-06-25

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 24

Registration Number: NCT00927563

Locations: 🇺🇸
Ambulatory Research Center, Minneapolis, Minnesota, United States

Delirium in Mechanically Ventilated Patients

Completed

Conditions: Delirium

First Posted Date: 2009-06-12

Last Posted Date: 2014-12-03

Lead Sponsor: University of Chicago

Target Recruit Count: 102

Registration Number: NCT00919698

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy